1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Evolution of Continuous Bioprocessing
3.3. Continuous Processing in the Pharmaceutical Industry
3.3.1. Regulatory Landscape
3.3.2. Early Adopters of the Technology
3.3.3. Anticipated Shift from Batch Processing
3.3.4. Advantages of Continuous Processing
3.3.5. Key Challenges Associated with Continuous Processing
3.3.6. Future Perspectives

4. MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Continuous and Semi-Continuous Bioprocessing: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Type of Manufacturer
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Company Size and Type of Manufacturer
4.2.6. Analysis by Location of Headquarters
4.2.7. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Innovators
4.2.8. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Contract Service Providers
4.2.9. Analysis by Type of Facility
4.2.10. Analysis by Type of Bioreactor
4.2.11. Analysis by Stage of Bioprocess
4.2.11.1. Primary Continuous and Semi-Continuous Bioprocessing
4.2.11.2. Secondary Continuous and Semi-Continuous Bioprocessing
4.2.12. Analysis by Types of Biologics Manufactured
4.2.13. Information on Production Capacity

5. CONTINUOUS BIOPROCESSING IN NORTH AMERICA: COMPANY PROFILES

5.1. Chapter Overview
5.2. AGC Biologics
5.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.2.2. Recent Developments and Future Outlook
5.3. Biogen
5.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.3.2. Recent Developments and Future Outlook
5.4. Bristol-Myers Squibb
5.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.4.2. Recent Developments and Future Outlook
5.5. Sanofi Genzyme
5.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
5.5.2. Recent Developments and Future Outlook

6. CONTINUOUS BIOPROCESSING IN EUROPE: COMPANY PROFILES
6.1. Chapter Overview
6.2. FUJIFILM Diosynth Biotechnologies
6.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.2.2. Recent Developments and Future Outlook
6.3. Merck KGaA
6.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.3.2. Recent Developments and Future Outlook
6.4. Novasep
6.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.4.2. Recent Developments and Future Outlook
6.5. UCB Pharma
6.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
6.5.2. Recent Developments and Future Outlook

7. CONTINUOUS BIOPROCESSING IN ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. Enzene Biosciences
7.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
7.2.2. Recent Developments and Future Outlook
7.3. WuXi Biologics
7.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
7.3.2. Recent Developments and Future Outlook

8. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS BIOPROCESSING CAPABILITIES

8.1. Chapter Overview
8.2. Continuous Manufacturing Initiatives of Leading Companies
8.2.1. AbbVie
8.2.1.1. Partnered Initiatives
8.2.1.2. In-House Initiatives
8.2.2. Amgen
8.2.2.1. Partnered Initiatives
8.2.2.2. In-House Initiatives
8.2.3. Bristol-Myers Squibb
8.2.3.1. Partnered Initiatives
8.2.3.2. In-House Initiatives
8.2.4. GlaxoSmithKline
8.2.4.1. Partnered Initiatives
8.2.4.2. In-House Initiatives
8.2.5. Merck
8.2.5.1. Partnered Initiatives
8.2.5.2. In-House Initiatives
8.2.6. Novartis
8.2.6.1. Partnered Initiatives
8.2.6.2. In-House Initiatives
8.2.7. Pfizer
8.2.7.1. Partnered Initiatives
8.2.7.2. In-House Initiatives
8.2.8. Roche
8.2.8.1. Partnered Initiatives
8.2.8.2. In-House Initiatives
8.2.9. Sanofi
8.2.9.1. Partnered Initiatives
8.2.9.2. In-House Initiatives

9. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGICS: MARKET LANDSCAPE

9.1. Chapter Overview
9.2. Continuous Manufacturing Equipment for Biologic Drugs: Overall Market Landscape
9.2.1. Analysis by Type of Equipment
9.2.2. Analysis by Type of Manufacturing Process
9.2.3. Analysis by Stage of Bioprocess
9.2.4. Analysis by Scale of Operation
9.3. Continuous Manufacturing Equipment Providers for Biologics
9.3.1. Analysis by Year of Establishment
9.3.2. Analysis by Company Size
9.3.3. Analysis by Location of Headquarters
9.3.4. Analysis by Prominent Continuous Manufacturing Equipment Providers

10. COST SAVING ANALYSIS

10.1. Chapter Overview
10.2 Technologies Involved in Continuous and Semi-Continuous Bioprocessing
10.3 Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing
10.3.1. Potential Cost Savings in Upstream Processes
10.3.2. Potential Cost Savings in Downstream Processes
10.4. Key Assumptions and Methodology
10.5 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocesses, 2021-2030
10.6 Concluding Remarks

11. CAPACITY ANALYSIS

11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3.1. Global, Continuous and Semi-Continuous Bioprocessing Capacity
11.3.2. Analysis by Company Size
11.3.3. Analysis by Type of Manufacturer
11.3.4. Analysis by Company Size and Type of Manufacturer
11.3.4. Analysis by Scale of Operation
11.3.5. Analysis by Location of Headquarters
11.3.6. Analysis by Location of Continuous and Semi-Continuous Bioprocessing Facilities

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030
12.3.1. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.3.2. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size
12.3.3. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.3.4. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess
12.3.5. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions
12.4. Continuous Upstream Bioprocessing Market, 2021-2030
12.4.1. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.4.2. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size
12.4.3. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.4.4. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions
12.5. Continuous Downstream Bioprocessing Market, 2021-2030
12.5.1. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
12.5.2. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size
12.5.3. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
12.5.4. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions

13. CONCLUSION

14. EXECUTIVE INSIGHTS

14.1. Chapter Overview
14.2. AstraZeneca
14.2.1. Overview of Company / Organization
14.2.2. Interview Transcript: Jon Coffman, Senior Director of Bioprocess Technology and Engineering
14.3. Enzene Biosciences
14.3.1. Overview of Company / Organization
14.3.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer
14.4. Albany College of Pharmacy and Health Sciences
14.4.1. Overview of Company / Organization
14.4.2. Interview Transcript: Ehsan Mahdinia, Assistant Professor

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Advantages of Continuous Bioprocessing
Figure 4.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
Figure 4.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
Figure 4.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
Figure 4.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
Figure 4.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
Figure 4.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
Figure 4.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Facilities of Innovators
Figure 4.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
Figure 4.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
Figure 4.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
Figure 4.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
Figure 4.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
Figure 4.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
Figure 4.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
Figure 4.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
Figure 8.1 Continuous Manufacturing Initiatives: AbbVie
Figure 8.2 Continuous Manufacturing Initiatives: Amgen
Figure 8.3 Continuous Manufacturing Initiatives: Bristol-Myers Squibb
Figure 8.4 Continuous Manufacturing Initiatives: GlaxoSmithKline
Figure 8.5 Continuous Manufacturing Initiatives: Merck
Figure 8.6 Continuous Manufacturing Initiatives: Novartis
Figure 8.7 Continuous Manufacturing Initiatives: Pfizer
Figure 8.8 Continuous Manufacturing Initiatives: Roche
Figure 8.9 Continuous Manufacturing Initiatives: Sanofi
Figure 9.1 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Figure 9.2 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Figure 9.3 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
Figure 9.4 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Figure 9.5 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Figure 9.6 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Figure 9.7 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Figure 9.8 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
Figure 10.1 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
Figure 10.2 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocess Techniques, 2021-2030 (USD Billion)
Figure 11.1 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
Figure 11.2 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
Figure 11.3 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
Figure 11.4 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
Figure 11.5 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
Figure 11.6 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
Figure 11.7 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
Figure 12.1 Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.2 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.3 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.4 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.5 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
Figure 12.6 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 12.7 Continuous Upstream Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.8 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.9 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.10 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.11 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 12.12 Continuous Downstream Bioprocessing Market, 2021-2030 (USD Million)
Figure 12.13 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Figure 12.14 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
Figure 12.15 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 12.16 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Figure 13.1 Concluding Remarks: Market Landscape
Figure 13.2 Concluding Remarks: Capacity Analysis
Figure 13.3 Concluding Remarks: Recent Expansions
Figure 13.4 Concluding Remarks: Cost Saving Analysis
Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis for Continuous and Semi-Continuous Bioprocessing Market

List of Tables
Table 3.1 Early Adopters of Continuous Bioprocess Technology
Table 3.2 Batch Processing Technique versus Continuous Processing Technique: Comparison of Characteristics
Table 4.1 List of Companies with Expertise in Continuous and Semi-Continuous Bioprocessing
Table 4.2 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Scale of Operation
Table 4.3 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Type of Facility and Type of Bioreactor
Table 4.4 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Stage of Bioprocess
Table 4.5 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Primary Continuous and Semi-Continuous Bioprocessing
Table 4.6 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Secondary Continuous and Semi-Continuous Bioprocessing
Table 4.7 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Types of Biologics Manufactured
Table 4.8 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Production Capacity
Table 5.1 AGC Biologics: Company Snapshot
Table 5.2 AGC Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.3 AGC Biologics: Recent Developments and Future Outlook
Table 5.4 Biogen: Company Snapshot
Table 5.5 Biogen: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.6 Biogen: Recent Developments and Future Outlook
Table 5.7 Bristol-Myers Squibb: Company Snapshot
Table 5.8 Bristol-Myers Squibb: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 5.10 Sanofi Genzyme: Company Snapshot
Table 5.11 Sanofi Genzyme: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 5.12 Sanofi Genzyme: Recent Developments and Future Outlook
Table 6.1 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 6.2 FUJIFILM Diosynth Biotechnologies: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.3 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.4 Merck KGaA: Company Snapshot
Table 6.5 Merck KGaA: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.6 Merck KGaA: Recent Developments and Future Outlook
Table 6.7 Novasep: Company Snapshot
Table 6.8 Novasep: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.9 Novasep: Recent Developments and Future Outlook
Table 6.10 UCB Pharma: Company Snapshot
Table 6.11 UCB Pharma: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 6.12 UCB Pharma: Recent Developments and Future Outlook
Table 7.1 Enzene Biosciences: Company Snapshot
Table 7.2 Enzene Biosciences: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 7.3 Enzene Biosciences: Recent Developments and Future Outlook
Table 7.4 WuXi Biologics: Company Snapshot
Table 7.5 WuXi Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
Table 7.6 WuXi Biologics: Recent Developments and Future Outlook
Table 8.1 AbbVie: Partnered Initiatives
Table 8.2 AbbVie: In-House Initiatives
Table 8.3 Amgen: Partnered Initiatives
Table 8.4 Amgen: In-House Initiatives
Table 8.5 Bristol-Myers Squibb: Partnered Initiatives
Table 8.6 Bristol-Myers Squibb: In-House Initiatives
Table 8.7 GlaxoSmithKline: Partnered Initiatives
Table 8.8 GlaxoSmithKline: In-House Initiatives
Table 8.9 Merck: Partnered Initiatives
Table 8.10 Merck: In-House Initiatives
Table 8.11 Novartis: Partnered Initiatives
Table 8.12 Novartis: In-House Initiatives
Table 8.13 Pfizer: Partnered Initiatives
Table 8.14 Pfizer: In-House Initiatives
Table 8.15 Roche: Partnered Initiatives
Table 8.16 Roche: In-House Initiatives
Table 8.17 Sanofi: Partnered Initiatives
Table 8.18 Sanofi: In-House Initiatives
Table 9.1 Continuous Manufacturing Equipment for Biologics: Information on Type of Equipment, Type of Manufacturing Process and Stage of Bioprocess
Table 9.2 Continuous Manufacturing Equipment for Biologics: Information on Scale of Operation and Throughput / Capacity
Table 9.3 Continuous Manufacturing Equipment Providers for Biologics: Information of Year of Establishment, Company Size and Location of Headquarters
Table 10.1 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Upstream Process
Table 10.2 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential of AcuSyst Perfusion Bioreactors
Table 10.3 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Downstream Process
Table 11.1 Global Continuous and Semi-Continuous Bioprocessing Capacity: Average Upstream Capacity by Company Size (Sample Data Set)
Table 14.1 AstraZeneca: Company / Organization Snapshot
Table 14.2 Enzene Biosciences: Company / Organization Snapshot
Table 14.3 Albany College of Pharmacy and Health Sciences: Company / Organization Snapshot
Table 15.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
Table 15.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
Table 15.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
Table 15.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
Table 15.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
Table 15.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
Table 15.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Innovators
Table 15.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
Table 15.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
Table 15.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
Table 15.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
Table 15.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
Table 15.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
Table 15.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
Table 15.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
Table 15. 16 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
Table 15.17 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
Table 15.18 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
Table 15.19 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
Table 15.20 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
Table 15.21 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
Table 15.22 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
Table 15.23 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
Table 15.24 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
Table 15.25 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing Techniques, 2021-2030 (USD Billion)
Table 15.26 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
Table 15.27 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
Table 15.28 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
Table 15.29 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
Table 15.30 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
Table 15.31 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
Table 15.32 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
Table 15.33 Overall Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030
Table 15.34 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.35 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.36 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.37 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
Table 15.38 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Table 15.39 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.40 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.41 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.42 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.43 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
Table 15.44 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 15.45 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
Table 15.46 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
Table 15.47 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
Table 15.48 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)

Companies Mentioned
The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 3D Biotek

2. 3P Biopharmaceuticals

3. AbbVie

4. ABL Europe

5. Abzena

6. Accenture

7. AGC Biologics

8. AIM ImmunoTech

9. Alexanderwerk

10. Alvotech

11. Amgen

12. AmpTec

13. Applikon Biotechnology

14. Aprogen

15. AstraZeneca

16. Avid Bioservices (formerly Peregrine Pharmaceuticals)

17. Baxter

18. Bayer

19. bbi-biotech

20. BIBITEC

21. BINEX

22. Biogen

23. BioMarin Pharmaceutical

24. Bionova Scientific

25. BiosanaPharma

26. Bio-Thera Solutions

27. Biovian

28. bluebird bio

29. Boehringer Ingelheim BioXcellence

30. Bonumose

31. Bristol-Myers Squibb

32. Changchun High & New Technology

33. Canton Biologics

34. CCHT Biopharmaceutical

35. Celgene

36. Cell and Gene Therapy Catapult

37. Cell Culture Company

38. CELLEC Biotek

39. Celonic

40. Centre for Process Innovation (CPI)

41. Cerbios-Pharma

42. CMAC

43. Cobra Biologics

44. Codiak BioSciences

45. Coperion

46. Creative Biolabs

47. CSL Behring

48. Cytiva

49. Cytovance Biologics

50. DCI-Biolafitte

51. DEVEX Verfahrenstechnik

52. DSM Pharmaceutical

53. Durham University

54. Eli Lilly

55. Engage Therapeutics (Acquired by UCB Pharma)

56. Enzene Biosciences

57. Eppendorf

58. Esco Aster

59. ETH Zurich

60. EV Biologics

61. Evotec

62. Exelixis

63. Exothera

64. Forbius

65. FUJIFILM Diosynth Biotechnologies

66. Gallus BioPharmaceuticals (Acquired by Patheon)

67. G-CON Manufacturing

68. GEA

69. Genzyme

70. Global BioTherapeutics (GBT)

71. Glycotope

72. Goodwin Biotechnology

73. GTP Technology

74. HAL Allergy

75. HALIX

76. Handl Therapeutics

77. Hemispherx Biopharma

78. HJB

79. Horizon Therapeutics

80. Janssen Pharmaceuticals

81. Johnson & Johnson

82. Just-Evotec Biologics

83. KBI Biopharma

84. Kemwell Biopharma

85. Kiadisto

86. Kymab

87. Lonza

88. Luina Bio

89. Lupin

90. MabSpace Biosciences

91. Medix Biochemica

92. Merck

93. Merck KGaA

94. Microsoft

95. MolMed

96. Mycenax Biotech

97. MyoKardia (acquired by Bristol-Myers Squibb)

98. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

99. National Resilience

100. Natrix Separations (Acquired by Merck)

101. Nightstar Therapeutics (acquired by Biogen)

102. Novartis

103. Novasep

104. Novavax

105. Novo Nordisk

106. Ology Bioservices

107. OmniBRx Biotechnologies

108. OXGENE (Acquired by WuXi AppTec)

109. PacificGMP

110. Pall Biotech

111. Pall Life Sciences

112. Pfizer

113. Pierre Fabre

114. PIERRE GUERIN

115. Polymun Scientific

116. ProBioGen

117. Rentschler Biopharma

118. Repligen

119. Sage Therapeutics

120. Samsung Biologics

121. Sangamo Therapeutics

122. Sanofi Genzyme

123. Sartorius

124. Semba Biosciences

125. Servier

126. Shire

127. Sturtevant

128. Syngene

129. Synthecon

130. TA Instruments

131. ThalesNano

132. The Rockefeller University

133. Thermo Fisher Scientific

134. Tidal Therapeutics (Acquired by Sanofi)

135. Transcenta

136. Translate Bio

137. UCB Pharma

Please contact our Customer Support Center to get the complete Table of Contents